Literature DB >> 17008421

N-glycolylneuraminic acid xenoantigen contamination of human embryonic and mesenchymal stem cells is substantially reversible.

Annamari Heiskanen1, Tero Satomaa, Sari Tiitinen, Anita Laitinen, Sirkka Mannelin, Ulla Impola, Milla Mikkola, Cia Olsson, Halina Miller-Podraza, Maria Blomqvist, Anne Olonen, Hanna Salo, Petri Lehenkari, Timo Tuuri, Timo Otonkoski, Jari Natunen, Juhani Saarinen, Jarmo Laine.   

Abstract

Human embryonic and mesenchymal stem cell therapies may offer significant benefit to a large number of patients. Recently, however, human embryonic stem cell lines cultured on mouse feeder cells were reported to be contaminated by the xeno-carbohydrate N-glycolylneuraminic acid (Neu5Gc) and considered potentially unfit for human therapy. To determine the extent of the problem of Neu5Gc contamination for the development of stem cell therapies, we investigated whether it also occurs in cells cultured on human feeder cells and in mesenchymal stem cells, what are the sources of contamination, and whether the contamination is reversible. We found that N-glycolylneuraminic acid was present in embryonic stem cells cultured on human feeder cells, correlating with the presence of Neu5Gc in components of the commercial serum replacement culture medium. Similar contamination occurred in mesenchymal stem cells cultured in the presence of fetal bovine serum. The results suggest that the Neu5Gc is present in both glycoprotein and lipid-linked glycans, as detected by mass spectrometric analysis and monoclonal antibody staining, respectively. Significantly, the contamination was largely reversible in the progeny of both cell types, suggesting that decontaminated cells may be derived from existing stem cell lines. Although major complications have not been reported in the clinical trials with mesenchymal stem cells exposed to fetal bovine serum, the immunogenic contamination may potentially be reflected in the viability and efficacy of the transplanted cells and thus bias the published results. Definition of safe culture conditions for stem cells is essential for future development of cellular therapies.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17008421     DOI: 10.1634/stemcells.2006-0444

Source DB:  PubMed          Journal:  Stem Cells        ISSN: 1066-5099            Impact factor:   6.277


  72 in total

Review 1.  The potential of adipose stem cells in regenerative medicine.

Authors:  Bettina Lindroos; Riitta Suuronen; Susanna Miettinen
Journal:  Stem Cell Rev Rep       Date:  2011-06       Impact factor: 5.739

Review 2.  Serum-free media for the production of human mesenchymal stromal cells: a review.

Authors:  S Gottipamula; M S Muttigi; U Kolkundkar; R N Seetharam
Journal:  Cell Prolif       Date:  2013-09-30       Impact factor: 6.831

Review 3.  Platelet lysate as replacement for fetal bovine serum in mesenchymal stromal cell cultures.

Authors:  Karen Bieback
Journal:  Transfus Med Hemother       Date:  2013-08-26       Impact factor: 3.747

4.  Derivation of multipotent nestin(+)/CD271 (-)/STRO-1 (-) mesenchymal-like precursors from human embryonic stem cells in chemically defined conditions.

Authors:  Rongrong Wu; Bin Gu; Xiaoli Zhao; Zhou Tan; Liangbiao Chen; Jiang Zhu; Ming Zhang
Journal:  Hum Cell       Date:  2011-06-15       Impact factor: 4.174

5.  Clinical Protocols for the Isolation and Expansion of Mesenchymal Stromal Cells.

Authors:  Karen Bieback; Katharina Schallmoser; Harald Klüter; Dirk Strunk
Journal:  Transfus Med Hemother       Date:  2008-07-17       Impact factor: 3.747

Review 6.  Potential barriers to therapeutics utilizing pluripotent cell derivatives: intrinsic immunogenicity of in vitro maintained and matured populations.

Authors:  Chad Tang; Micha Drukker
Journal:  Semin Immunopathol       Date:  2011-04-11       Impact factor: 9.623

7.  Differential gene expression in adipose stem cells cultured in allogeneic human serum versus fetal bovine serum.

Authors:  Bettina Lindroos; Kaisa-Leena Aho; Hannu Kuokkanen; Sari Räty; Heini Huhtala; Riina Lemponen; Olli Yli-Harja; Riitta Suuronen; Susanna Miettinen
Journal:  Tissue Eng Part A       Date:  2010-07       Impact factor: 3.845

8.  Clinical-scale in vitro expansion preserves biological characteristics of cardiac atrial appendage stem cells.

Authors:  S Windmolders; L Willems; A Daniëls; L Linsen; Y Fanton; M Hendrikx; R Koninckx; J-L Rummens; K Hensen
Journal:  Cell Prolif       Date:  2015-01-29       Impact factor: 6.831

9.  Reduction of N-glycolylneuraminic acid in human induced pluripotent stem cells generated or cultured under feeder- and serum-free defined conditions.

Authors:  Yohei Hayashi; Techuan Chan; Masaki Warashina; Masakazu Fukuda; Takashi Ariizumi; Koji Okabayashi; Naoya Takayama; Makoto Otsu; Koji Eto; Miho Kusuda Furue; Tatsuo Michiue; Kiyoshi Ohnuma; Hiromitsu Nakauchi; Makoto Asashima
Journal:  PLoS One       Date:  2010-11-23       Impact factor: 3.240

10.  Sensitive and specific detection of the non-human sialic Acid N-glycolylneuraminic acid in human tissues and biotherapeutic products.

Authors:  Sandra L Diaz; Vered Padler-Karavani; Darius Ghaderi; Nancy Hurtado-Ziola; Hai Yu; Xi Chen; Els C M Brinkman-Van der Linden; Ajit Varki; Nissi M Varki
Journal:  PLoS One       Date:  2009-01-21       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.